Pages
Ads
Categories
- Allergies pills
- Anthelmintics
- Anti Convulsants Pills
- Anti Depressants Pills
- Antibiotics Pills
- AntiViralPill
- Arthritis pills
- Blood Pressure Pills
- Cholesterol Pills
- Diabetes Pills
- Diuretics pills
- eBook download
- Erectile Dysfunction Pills
- Gastrointestinal Pills
- Heartburn Pills
- herbal
- Hypertension pills
- Images pills
- Inflammatory
- Mens Health pills
- Muscle Relaxant Pills
- News
- Other pills
- Pain Relief Pills
- Review prices
- Skin Care Pills
- Stop Smoking Pills
- Uncategorized
- Video about ED pills
- Weight Loss Pills
- Women's Health Drugs
Blogroll
- Acne Treatment Tips
- Acomplia blog
- Advanced whois
- Cialis vs Levitra
- Diet Recipes Blog
- Flexyx A-Z drugs
- Generic Cialis soft tabs
- Home Health Agencies
- Learn How to Overcome Depression
- Safe Net Pharmacy
- Traumatology and Orthopaedics
- Viagra
- FDA Approves Janumet XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of Janumet (sitagliptin/metformin HCl) Now Available with Once-Daily Convenience
- FDA Approves Jentadueto (linagliptin/metformin hydrochloride) for the Treatment of Adult Patients with Type 2 Diabetes
- FDA Approves Gleevec for Expanded Use in Patients with Rare Gastrointestinal Cancer
- FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis
- FDA Approves Erivedge for Basal Cell Carcinoma
- FDA Approves Bydureon - The First and Only Once-Weekly Treatment for Type 2 Diabetes
- FDA Approves Inlyta for Advanced Renal Cell Carcinoma
- FDA Approves Picato (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
- UCB Announces FDA Approval for Keppra in Infants and Children from One Month of Age with Partial Onset Seizures
- New FDA Approved Labeling For Vytorin (ezetimibe/simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
Tags
ads
Universal flu
January 5, 2008
A single jab that could give lifelong protection against all types of flu has produced promising results in human trials.
The vaccine, made by Acambis, should protect against all strains of influenza A - the cause of pandemics. Currently, winter flu jabs have to be regularly redesigned because the flu virus keeps changing.
The new vaccine would overcome this and could be stockpiled in advance of a bird flu outbreak, say experts.
Each year winter flu kills around 4,000 people in the UK. Globally, between 500,000 and one million people die each year from influenza. But a pandemic of the human form of bird flu, which experts believe is inevitable, could kill as many as 50m people worldwide. The US trials show that the jab is safe and it works fast to make the body immune against flu. Nine out of 10 of those who had two doses of the jab ACAM-FLU-A developed antibodies against flu virus. Scientists at Acambis are now working to perfect the formulation before doing larger human trials. Dr Michael Watson of Acambis said: “As a universal vaccine, ACAM-FLU-A can potentially overcome many of the drawbacks of existing influenza vaccines. “It can be manufactured at any time of the year, and could be stockpiled in advance of a pandemic or potentially used routinely to ensure population protection against future pandemics.”
Unique action
Current flu vaccines work by giving immunity to two proteins called haemagglutinin and neuraminidase, which are found on the surface of flu viruses. However, these proteins keep mutating which means doctors have to keep making new vaccines to keep up. The Acambis vaccine homes in on a different protein, called M2, which is found on the surface of all A-strains of flu and does not appear to mutate so readily. Professor Ian Jones, a University of Reading virologist, said the jab could end the scramble to produce a new winter jab each year. But he said it would still be some years before it was widely available for patients. “Larger trials and tests on a wider range of viruses will be needed before the full potential for pandemic protection can be assured,” he said.
Posted in: AntiViralPill, News | |
No Comments »
No comments yet.
Fatal error: Call to undefined function post_comments_feed_link() in /var/www/viptabs/data/www/news.drugrxus.com/wp-content/themes/apple/comments.php on line 29